公开(公告)号：WO2006051106A1

公开(公告)日：2006-05-18

申请号：PCT/EP2005/055931

申请日：2005-11-11

Applicant: BioXell SpA ,  ADORINI, Luciano ,  PENNA, Giuseppe

Inventor： ADORINI, Luciano ,  PENNA, Giuseppe

IPC: A61K31/59 ,  A61K31/70 ,  A61K31/7008 ,  A61P13/10 ,  A61P35/00

CPC classification number: A61K31/59 ,  A61K31/70 ,  A61K31/7008 ,  A61K2300/00

Abstract: There is provided according to the invention a method of treating a patient with bladder cancer by administering a effective amount of a vitamin D compound in combination with one or more other antiproliferative agents. Also provided are uses of a vitamin D compound in combination with one or more other antiproliferative agents and compositions for use in the method.

Abstract translation: 根据本发明提供了通过与一种或多种其它抗增殖剂组合施用有效量的维生素D化合物来治疗膀胱癌患者的方法。 还提供维生素D化合物与一种或多种其它抗增殖剂和用于该方法的组合物的组合的用途。

公开(公告)号：WO2006024140A1

公开(公告)日：2006-03-09

申请号：PCT/CA2005/001293

申请日：2005-08-26

Applicant: ANASTASSIADES, Tassos

Inventor： ANASTASSIADES, Tassos

IPC: A61K31/7008

CPC classification number: A61K31/7008

Abstract: A method of treating a mammal for a purpose selected from the group consisting of (a) increasing bone mineral density (BMD), (b) treating low BMD, (c) preventing and treating low impact fractures, (d) treating high impact fractures; (e) treating osteoporosis; (f) modulating a growth factor that influences bone metabolism; and (g) improving bone micro-architecture or connectivity; the method comprising administering to the mammal an effective amount of a N-acylated-2-glucosamine derivative of the general formula (I)., wherein R is an alkyl radical of the general formula C n H 2n, + 1 and n is selected from 2-12; or pharmaceutically-acceptable salts, esters and glucosides thereof; or pharmaceutically acceptable compositions thereof, and particularly wherein R is C 3 H 7 .

Abstract translation: 一种治疗哺乳动物的方法，其选自（a）增加骨矿物质密度（BMD），（b）治疗低BMD，（c）预防和治疗低冲击性骨折，（d）治疗高度影响性骨折 ; （e）治疗骨质疏松症; （f）调节影响骨代谢的生长因子; 和（g）改善骨骼微结构或连接性; 所述方法包括向哺乳动物施用有效量的通式（I）的N-酰化-2-葡糖胺衍生物，其中R是通式C的烷基， n 2，n + 1，n选自2-12; 或其药学上可接受的盐，酯和葡糖苷; 或其药学上可接受的组合物，特别是其中R为C 3 H 7。

公开(公告)号：WO2006021653A2

公开(公告)日：2006-03-02

申请号：PCT/FR2005001851

申请日：2005-07-20

Applicant: SANOFI AVENTIS ,  DRIGUEZ PIERRE ALEXANDRE ,  PETITOU MAURICE

Inventor： DRIGUEZ PIERRE ALEXANDRE ,  PETITOU MAURICE

IPC: C07H3/06 ,  A61K31/7008 ,  A61K31/702 ,  A61P35/00 ,  C07H5/06

CPC classification number: C07H5/06 ,  C07H3/06

Abstract: The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a -OSO 3 - radical, a -O-(C 1 -C 5 )alkyl radical or an -O- aralkyl radical; Z represents a COO - radical or a hydroxyl radical; X represents -OH or a saccharide unit of formula A, Y represents H, C 1 -C 5 alkyl or a saccharide unit of formula D; in free form or in the form of pharmaceutically acceptable salts formed with a base or an acid as well as in the form of solvates or hydrates. The derivatives of the invention are useful as medicines.

Abstract translation: 本发明涉及通式（I）的乙酰肝素酶抑制化合物，其中R表示氢原子，羟基，-OSO 3 - 基，-O-（C 1 H 3） -C 5 -C 5烷基或-O-芳烷基; Z代表COO - 或 - 羟基; X表示-OH或式A的糖单元，Y表示H，C 1 -C 5烷基或式D的糖单元; 游离形式或以与碱或酸形成的药学上可接受的盐以及溶剂合物或水合物形式的形式。 本发明的衍生物可用作药物。

公开(公告)号：WO2006011592A1

公开(公告)日：2006-02-02

申请号：PCT/JP2005/013916

申请日：2005-07-29

Applicant: 湧永製薬株式会社 ,  下川 義之 ,  白石 澄廣 ,  三原 美香

Inventor： 下川 義之 ,  白石 澄廣 ,  三原 美香

IPC: A61K9/64 ,  A61K9/56 ,  A61K31/19 ,  A61K31/661 ,  A61K31/7008 ,  A61P3/00 ,  A23L1/00

CPC classification number: A61K9/4825 ,  A61K9/2873

Abstract: 　本発明は、ゼラチン皮膜の経時的な溶解性低下をより高度に抑制し、特に軟カプセル剤の場合、同時にカプセルに十分な強度を付与するカプセル皮膜用組成物、並びにこれを用いたカプセル皮膜及びカプセル剤を提供する。該カプセル皮膜用組成物は、ゼラチン（Ａ）と一般式Ｃ ６ Ｈ １２－ｎ ・（Ｈ ２ ＰＯ ４ ） ｎ （式中、ｎは１～６の整数を表す）で表されるイノシトールリン酸（Ｂ）とを含むことを特徴とする。

Abstract translation: 用于胶囊膜形成的组合物，其有效地更高度地抑制明胶膜的溶解度随时间的降低，并且特别是当施用于软胶囊时，与胶囊同时赋予胶囊足够的强度; 以及由该组合物形成的胶囊膜和胶囊。 该组合物的特征在于包含由通式C 6 H 12-n H（H 2）表示的明胶（A）和磷酸肌醇（B） （其中n为1-6的整数）。

公开(公告)号：WO2005097142A1

公开(公告)日：2005-10-20

申请号：PCT/AU2005/000506

申请日：2005-04-07

Applicant: ALCHEMIA LIMITED ,  HALLIDAY, Judy ,  MEUTERMANS, Wim ,  TOMETZKI, Gerald ,  RAMSDALE, Tracie, Elizabeth ,  ZUEGG, Johannes ,  BECKER, Bernd ,  MULDOON, Craig ,  MCKEVENEY, Declan ,  PREMRAJ, Rajaratnam ,  CONDIE, Glenn

Inventor： HALLIDAY, Judy ,  MEUTERMANS, Wim ,  TOMETZKI, Gerald ,  RAMSDALE, Tracie, Elizabeth ,  ZUEGG, Johannes ,  BECKER, Bernd ,  MULDOON, Craig ,  MCKEVENEY, Declan ,  PREMRAJ, Rajaratnam ,  CONDIE, Glenn

IPC: A61K31/7008

CPC classification number: A61K31/7008 ,  A61K31/70

Abstract: A method for inhibiting angiogenesis in a subject comprising administering to the subject at least one compound of General Formula (I), wherein the ring or any chiral center(s) may be of any configuration; Z is sulphur, oxygen, CH2, C(O), C(O)HN, NH, NRA or hydrogen, in the case where Z is hydrogen then R1 is not present, RA is selected from the set defined for R1 to R5, X and X' are independently oxygen or nitrogen providing that at least one X of General Formula (I) is nitrogen, X or X' may also combine independently with one of R1 to R5 to form an azide, R1 to R5 are independently selected from the following definition which includes but is not limited to H or an alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituent of 1 to 20 atoms, which is optionally substituted, and can be branched or linear, and R6 and R7 are hydrogen, or may combine to form a carbonyl function.

Abstract translation: 一种用于抑制受试者血管发生的方法，其包括向所述受试者施用至少一种通式（I）的化合物，其中所述环或任何手性中心可以是任何构型; Z是硫，氧，CH 2，C（O），C（O）HN，NH，NRA或氢时，在Z是氢的情况下，R1不存在，RA选自为R1至R5定义的集合， X和X'独立地是氧或氮，条件是至少一个通式（I）的X是氮，X或X'也可以独立地与R 1至R 5中的一个组合形成叠氮化物，R 1至R 5独立地选自 包括但不限于H或任选取代的1-20个原子的烷基，酰基，烯基，炔基，杂烷基，芳基，杂芳基，芳烷基或杂芳基烷基取代基，并且可以是支链或直链的以下定义，和 R6和R7是氢，或者可以结合形成羰基官能团。

公开(公告)号：WO2005053710A3

公开(公告)日：2005-08-04

申请号：PCT/EP2004013184

申请日：2004-11-19

Applicant: NESTEC SA ,  COURTOIS DIDIER ,  MICHAUX STEPHANE ,  PETIARD VINCENT ,  TOUCHE ANDRE

Inventor： COURTOIS DIDIER ,  MICHAUX STEPHANE ,  PETIARD VINCENT ,  TOUCHE ANDRE

IPC: A23B4/03 ,  A23G3/00 ,  A23G3/36 ,  A23K1/14 ,  A23K1/16 ,  A23K1/18 ,  A23L1/30 ,  A61K8/60 ,  A61K8/97 ,  A61K31/7008 ,  A61Q5/00 ,  A61Q19/08 ,  A61K35/78

CPC classification number: A61K31/7008 ,  A23G3/36 ,  A23K10/30 ,  A23K20/163 ,  A23K50/42 ,  A23K50/48 ,  A23L33/105 ,  A23V2002/00 ,  A61K8/60 ,  A61K8/97 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q19/08 ,  A23V2250/308 ,  A23V2200/318 ,  A23V2200/306

Abstract: The present invention relates to an orally ingestible food or pet food composition or cosmetic composition containing glucosamine generated from plant materials through a drying process for the maintenance of joint health or prevention, alleviation and/or treatment of osteoarthritis, or the improvement of the skin quality and prevention or restoration of age-related alterations of skin. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat, a medicament or a cosmetic product and methods for the maintenance of bone health, prevention, alleviation and/or treatment of osteoarthritis, improvement of the skin quality and prevention or restoration of age-related alterations of skin which comprises administering an effective amount of the composition.

Abstract translation: 本发明涉及通过用于维持关节健康或预防，减轻和/或治疗骨关节炎的干燥方法从植物材料产生的含有葡糖胺的口服摄取食物或宠物食品组合物或化妆品组合物，或提高皮肤质量 并预防或恢复年龄相关的皮肤改变。 它还涉及组合物在制造营养产品，补充剂，治疗剂，药物或化妆品中的用途以及用于维持骨骼健康，预防，缓解和/或治疗骨关节炎的方法，改善 皮肤质量和预防或恢复皮肤年龄相关的改变，其包括施用有效量的组合物。

公开(公告)号：WO2004084915A1

公开(公告)日：2004-10-07

申请号：PCT/CN2004/000280

申请日：2004-03-29

IPC: A61K31/7008

CPC classification number: A61K31/7008

Abstract: The invention relates to the use of N-acetyl-D-an-finoglycosamine in preparation of drugs for treatment of non-specific inflammations related to physical or chemical factors, or for control of symptoms thereof. Nacetyl-D­aminoglycosamine as an active ingredient in formulations is used in treatment of non-specific inflammations related to physical or chemical factors, with significant therapeutic effects and no side effects.

公开(公告)号：WO2004084914A1

公开(公告)日：2004-10-07

申请号：PCT/CN2004/000276

申请日：2004-03-29

IPC: A61K31/7008

CPC classification number: A61K31/7008

Abstract: The invention relates to the use of N-acetyl-D-aminoglycosamine and a pharmaceutically acceptable salt thereof in preparation of drugs for treatment of organ lesions related to toxicosis of drugs or chemicals. N-acetyl-D­aminoglycosamine as an active ingredient in formulations is used in treatment of organ lesions related to toxicosis of drugs or chemicals, with significant therapeutic effects and no side effects.

公开(公告)号：WO03086267B1

公开(公告)日：2004-04-29

申请号：PCT/US0310816

申请日：2003-04-09

Applicant: MILLER FRED H ,  AUSEC LANCE R

Inventor： MILLER FRED H ,  AUSEC LANCE R

IPC: A61J3/07 ,  A61K9/48 ,  A61K9/52 ,  A61K9/64 ,  A61K31/12 ,  A61K31/135 ,  A61K31/138 ,  A61K31/192 ,  A61K31/202 ,  A61K31/355 ,  A61K31/365 ,  A61K31/375 ,  A61K31/415 ,  A61K31/7008 ,  A61K31/7076 ,  A61K31/737 ,  A61K45/06 ,  A61K47/32 ,  A61K47/36 ,  A61K47/42 ,  B29C39/10

CPC classification number: B29C39/10 ,  A61J3/071 ,  A61K9/4808 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K45/06 ,  B29K2105/0061

Abstract: A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

Abstract translation: 一种多室胶囊，包括：第一容纳室，其包含至少一种具有第一物理状态的成分，其中所述成分选自营养品，维生素，膳食补充剂和矿物质; 和包含至少一种具有第二物理状态的成分的第二接收室，其中所述成分选自营养食品，维生素，膳食补充剂和矿物质; 其中所述第一接收室的所述成分的所述第一物理状态不同于所述第二接收室的所述成分的所述第二物理状态; 并且所述第一接收室的所述成分不同于所述第二接收室的所述成分。

公开(公告)号：WO03004734A9

公开(公告)日：2003-04-10

申请号：PCT/US0144081

申请日：2001-10-22

Applicant: MEMC ELECTRONIC MATERIALS

Inventor： VORONKOV VLADIMIR ,  FALSTER ROBERT J ,  BANAN MOHSEN

IPC: C30B29/06 ,  A61K31/427 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7008 ,  A61K31/704 ,  C30B15/00 ,  C30B15/20

CPC classification number: C30B29/06 ,  A61K31/427 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7008 ,  A61K31/704 ,  C30B15/203 ,  C30B15/206

Abstract: A process for the preparation of a silicon single ingot in accordance with the Czochralski method. The process for growing the single crystal silicon ingot comprises controlling (i) a growth velocity, v, (ii) an average axial temperature gradient, G0, during the growth of a constant diameter portion of the crystal over a temperature range from solidification to a temperature of no less than about 1325 C to initially produce in the constant diameter portion of the ingot a series of predominant intrinsic point defects including vacancy dominated regions and silicon self interstitial dominated regions, alternating along the axis, and cooling the regions from the temperature of solidification at a rate which allows silicon self-interstitial atoms to diffuse radially to the lateral surface and to diffuse axially to vacancy dominated regions to reduce the concentration intrinsic point defects in each region.

Abstract translation: 根据Czochralski法制备硅单锭的方法。 用于生长单晶硅锭的方法包括：在凝固的恒定直径部分的晶体生长过程中控制（i）生长速度v，（ii）平均轴向温度梯度G0， 温度不低于约1325℃，以在锭的恒定直径部分中初始生产一系列主要的本征点缺陷，包括空位主导区域和硅自填隙主导区域，沿着轴线交替，并且从区域的温度 以允许硅自间隙原子径向扩散到侧表面并且轴向扩散到空位主导区域的速率固化以减少每个区域中的固有点缺陷的浓度。